Introduction
Renal cell carcinoma (RCC) is the sixth leading cause of cancer deaths in Western countries and is the most lethal urologic tumor (Clark, 2007) . RCC is represented in 80% of the cases by clear cell renal cell carcinoma (CCC), originating from the renal proximal tubule. RCC is characterized by a high degree of resistance to conventional therapies. Recent studies yielded a better knowledge of the molecular mechanisms of kidney tumorigenesis, and led to the latest development of targeted anti-angiogenic strategies now used as first-line therapy for RCC (Escudier et al., 2008 (Escudier et al., , 2009 Motzer et al., 2009) .
The majority of CCC cases are characterized by inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene leading to the loss of VHL proteins (Friedrich, 1999; Carroll and Ashcroft, 2006; Kaelin, 2007; Baldewijns et al., 2010) . It should be stressed that the best known oncogenic signal in human CCC so far is constituted by the VHL/hypoxia-inducible factor (HIF) system. However, genetic and molecular studies clearly show that additional events are required for kidney tumorigenesis. In that context, the idea that tumors hijack signaling pathways and molecular factors/markers involved in normal development for their own growth has recently taken hold of investigators. Consequently, Sjolund et al. (2008) and Hueber et al. (2006 Hueber et al. ( , 2008 have shown that the developmental Notch signaling cascade and Pax2, critical for nephrogenesis, are constitutively active in human CCC cell lines and have growth-promoting effect. More recently, we have reached similar conclusions concerning the involvement of the developmental sonic hedgehog (SHH) signaling pathway in human CCC progression, and we showed further that the SHH signaling pathway has orchestral roles in the activation of oncogenic pathways in this disease, including the phosphoinositide kinase-3 (PI3K)/ Akt, the nuclear factor-kappaB (NF-kB) and mitogenactivated protein kinase (MAPK) signaling pathways (Dormoy et al., 2009) . This is particularly important as all these pathways, critical during kidney development (Reidy and Rosenblum, 2009) , are constitutively reactivated in CCC tumors (Sourbier et al., 2006 Schedl, 2007; Huang et al., 2008) .
Another very important genetic marker of nephrogenesis is the transcription factor LIM-class homeobox gene Lim1. Lim1 is specific to the vertebrate gastrula organizer and is required for proper cell movements during gastrulation (Venegas-Ferrin et al., 2010) . Lim1 has particular biological functions in brain and kidney (Kobayashi et al., 2005) . Invalidation of the Lim1 gene in mice led to kidney agenesis because of nephric duct formation failure (Shawlot and Behringer, 1995) . Lim1 is a downstream target of Pax2, and the tissue-specific deletion of the Lim1 gene in the metanephric mesenchyme halts development at the renal vesicle stage (Kobayashi et al., 2005; Reidy and Rosenblum, 2009) .
To date and to our knowledge, no studies have been conducted to assess the role of Lim1 in human CCC tumorigenesis. In our recent studies dealing with the involvement of the SHH pathway in human CCC progression (Dormoy et al., 2009) , we observed that Lim1 expression was under the regulation of the SHH pathway through the activity of the Glis transcription factors and that, more interestingly it appears to be exclusively expressed in tumors compared with the normal corresponding tissues in nine tumor/normal tissue pairs sampling. These data, added to the importance of Lim1 in fundamental steps of kidney development, including Notch pathways regulation, prompted us to study whether this transcription factor is part of the molecular mechanisms involved in human kidney progression; and consequently, whether targeting Lim1 may have therapeutic potential against this therapy-refractory disease.
Results

Lim1 transcription factor is constitutively expressed in human CCC cells independently of VHL expression
In contrast to normal human kidney, Lim1 expression was detected in a panel of human CCC cell lines expressing or not VHL either endogenously, or by gene transfer at both messenger RNA ( Figure 1a ) and protein ( Figure 1b ) levels, and there was no difference in expression depending on the VHL status.
Lim1 is exclusively reexpressed in human CCC tumors
We have shown, very recently, by western blot analysis on nine normal/tumoral tissue pairs that Lim1 is almost exclusively reexpressed in tumors (Dormoy et al., 2009) . Here, we have considerably extended this analysis. Indeed, on 44 normal/tumoral CCC pairs at all stages (Supplementary Table 1 ), Lim1 expression was largely expressed in tumors, whereas normal corresponding tissues showed low or no signal at both messenger RNA ( Figure 2a ) and protein ( Figure 2b ; Supplementary Table 1) levels. The difference in Lim1 expression in tumors vs normal tissues was highly significant and there was no difference in Lim1 expression depending on the tumoral stage and grade (Figure 2b ; Supplementary Table 1) .
Lim1 silencing decreases human CCC cell proliferation independently of VHL expression As there are no chemical inhibitors of Lim1, we silenced Lim1 expression in human CCC cells using specific Lim1-targeting siRNAs (siLhx1) targeting Lim1 exon-1 (siLhx1ex1), 2 (siLhx1ex2) or 3 (siLhx1ex3). The transient transfection of 786-0 cells with siLhx1ex1 (20, 50 and 100 nM) for 0-96 h significantly decreased Lim1 expression in a time-dependent manner and up to 90-95% at 96 h after transfection, as assessed by quantitative reverse transription-PCR ( Figure 3a ) and western blot (Figure 3b) , showing the high specificity and efficiency of Lim1 targeting. Similar results were obtained with siLhx1ex2 and siLhx1ex3 (data not shown).
In transient transfection assays, siLhx1ex1 decreased 786-0 cell growth in a time and concentration-dependent manner up to 60% at all time points (Supplementary Figure 1a) . Similar effects were obtained on 786-0 cell growth with the maximal concentration of all three Lim1-targeting small interfering RNAs (siRNAs) at all time points (Supplementary Figure 1b) . Such effects were also observed in our panel of human CCC cell lines expressing or not the VHL gene (Supplementary Figure 1c) .
To confirm the effects of Lim1 silencing on cell growth, we transiently transfected human 786-0 cells with human Lim1 expression vector (pCMV6-XL5- Figure 2) . Interestingly, the transfection with Lim1 vector significantly increased cell growth at 48, 72 and 96 h after transfection by up to 20-25% and substantially decreased the inhibitory effect of Lim1 silencing on cell growth (Supplementary Figure 2) . The effect of Lim1 silencing on cell growth was due in a large part to the inhibition of cell proliferation as assessed by Bromodeoxyuridine incorporation studies in our panel of human CCC cells, with a maximal inhibitory effect of 60-70%, again independently of VHL expression (Figures 3c and d; Supplementary  Figure 3 ).
Lim1 silencing increases human CCC cell apoptosis, but not senescence As the effect of Lim1 silencing on cell proliferation was not complete, we also checked whether the inhibitor was inducing apoptosis in human CCC cells. The transient transfection of 786-0 and Caki-1 cells with siLhx1ex1 was inducing cell apoptosis in a time-dependent manner reaching a maximal induction of cell apoptosis at 72 h of 10.1% ( ± 2.8) in 786-0 cells (Figure 4a ) and 12.1% (±3.8) in Caki-1 cells (Figure 4b ). No effects of siLhx1 treatment were observed on tumor cell senescence (Supplementary Figure 4) .
Thus, the effect of Lim1 silencing on cell growth is obtained mainly through the inhibition of cell proliferation and, to a lesser, but significant degree, through the induction of cell apoptosis in human CCC.
Lim1 silencing decreases human CCC cell motility, migration and invasion As Lim1 is critically involved in cell movements during nephrogenesis, we investigated whether Lim1 affects human CCC cell motility, migration and invasion. Cell motility was assessed by wound healing assay on both 786-0 (VHL deficient) and Caki-1 (expressing VHL) cells. The transient transfection of siLhx1ex1 concentration-and time-dependently decreased 786-0 cell motility by up to 70% at 12 and 24 h after transfection ( Figures  5a and b) . Similar results were obtained in Caki-1 cells (data not shown).
Cell migration and invasion were analyzed using Matrigel migration and invasion assays in both 786-0 and Caki-1 cells, respectively. As for motility assay, Lim1 silencing decreased 786-0 cell migration ( Figure 5c ) and invasion (Figure 5d ), concentration-and time-dependently by up to 50% at 24 h after transfection. Similar results were obtained in Caki-1 cells (data not shown).
We went deeper into these investigations by analyzing the expression of markers involved in cell adhesion and movement, including MMP9, tenascin-C, fibronectin, paxillin, actin and tubulin, which have all shown to be involved in CCC invasiveness. In 786-0 cells transiently transfected with siLhx1ex1, the expression of all of these proteins was substantially decreased in a dose-and timedependent manner (Figure 5e ).
Taken together, these results show that Lim1 is part of the machinery orchestrated by human CCC tumor cells to migrate, and thus to potentially invade extrarenal sites.
Lim1 regulates cell growth through multiple signaling pathways and factors in human CCC As we have previously shown that Lim1 expression is, at least in part, the consequence of the reactivation of the SHH-Gli pathway that has an orchestral role in the activation of oncogenic pathways in that pathology, we first evaluated whether Lim1 has a role in the constitutive activation of such pathways in human CCC. We used 786-0 cells transiently transfected with siLhx1ex1 alone or in combination with inhibitors of Lim1 in renal cell carcinoma V Dormoy et al was higher when combined with GSK-3, NF-kB or MAPK inhibitors than when alone, although nonadditive. These results suggest that Lim1 is linked to the activity of GSK-3 and to the oncogenic PI3K/Akt and NF-kB pathways, but not to the MAPK pathways. By western blot, the non-phosphorylated states of GSK-3, Akt, NF-kB and extracellular signal-regulated kinase 1/2 (Erk1/2) remained unchanged after Lim1 silencing ( Figure 6b ). As expected from cell growth data, the phosphorylation state of Akt and NF-kB decreased as a consequence of Lim1 depletion. However, unexpectedly, GSK-3 and Erk1/2 phosphorylations were not affected by siLhx1ex1 (Figure 6b ).
To get more insight into the mechanism accounting for the Lim1 effect on tumor cell growth, we used proteome Profiler Arrays (coated with apoptotic, phosphoproteins or angiogenesis pathways/markers) in 786-0 cells transiently transfected for 24 or 48 h with siLhx1ex1 or in control. Various signaling pathways and molecular factors involved in cell apoptosis, prolifera- Lim1 in renal cell carcinoma V Dormoy et al tion and movements, and in angiogenesis were found to be regulated at level of expression and/or activation directly or indirectly by Lim1 (Figures 7a, b and c) including phosphorylated Akt, Stats, cytochrome c, Fas, Bad, ROR, phosphorylated Erk1/2, p27, p38, p53; the FGF, PDGF and EGF receptors as well as markers of cell movements MMP8 and 9. It is notable that the activation of Erk1/2 was only observed using this latter method.
These results strongly suggest that Lim1 has a pivotal role in the expression and/or activation of various oncogenic and angiogenic pathways in human RCC (Figure 7d ).
Lim1 depletion blocks tumor progression in human CCC tumors-bearing nude mice
We next analyzed the effect of Lim1 silencing using siLhx1ex1 and siLhx1ex2 in vivo in the tumor xenografted nude mice model.
The expression of Lim1 substantially decreased in tumors harvested from siLhx1ex1-or siLhx1ex2-treated mice by around 80% compared with tumors from control-treated mice, showing adequate targeting of the drug (Figure 8a ). Tumor growth was almost completely abolished in the group treated with either Lim1-targeting siRNA in comparison with the control groups receiving the diluent alone or the control siRNA, which Ctl siLhx1 (100nM) P-HGFR P-EGFR P-ROR P-ERK1/2 P-AMPKα1 P-Akt β-cat P-c-jun P-paxillin P-p38α
Fas XIAP cyt c P-STAT pan P-p53 P-eNOS P-CREB P-HSP27 SMAC/Diablo HSP60 HSP70 P-HGFR P-EGFR P-ROR P-ERK1/2 P-AMPKα1 P-Akt β-cat P-c-jun P-paxillin P-p38α Figure 5c ). In tumors grown in nude mice and treated with either siLhx1ex1 or siLhx1ex2, the activation of the oncogenic pathways PI3K/Akt and NF-kB was substantially decreased, but not the activation of GSK-3 and of MAPK (Supplementary Figure 5d ), as observed in cultured cells. Similarly, the expression of the cell movement markers was also impaired in Lim1-depleted tumors (Supplementary Figure 5e ). These results show that Lim1 has a critical role in human CCC tumor growth, and that it is mainly turned towards cell proliferation, inhibition of cell death, activation of oncogenic pathways and stimulation of cell movements' markers in the in vivo environment.
Discussion
Lim1 has essential functions during several stages of kidney development, from the early mesenchyme-toepithelium transition to nephron patterning. We have recently shown that the developmental SHH-Gli signaling is reactivated in human CCC and that Lim1 is a SHH-Gli signaling target (Dormoy et al., 2009) . Here, we show that Lim1 is expressed in our panel of human CCC cells and that Lim1 is exclusively reexpressed in human tumors compared with normal corresponding tissues, thus extending substantially the results of our previous studies on Lim1 expression in CCC tumors (Dormoy et al., 2009) . There was no difference in Lim1 expression depending on the tumoral stage and grade, suggesting that Lim1 expression levels are maintained throughout CCC growth. Thus, Lim1 has the potential to serve as a diagnostic biomarker at least for CCC, but this would require many validation steps on a much larger range of tumors/normal tissues samples, and this would be quite important as no molecular diagnostic markers have yet been validated for this disease (Nogueira and Kim, 2008; Arsanious et al., 2009) .
Our group and other investigators have reported the critical role played by the oncogenic PI3K/Akt, NF-kB and MAPK signaling pathways as well as by the developmental Notch and SHH-Gli signaling in human CCC tumorigenesis (Sourbier et al., 2006 Huang et al., 2008; Sjolund et al., 2008; Dormoy et al., 2009) . In all cases, these pathways were shown to be constitutively activated and turned towards tumor growth regardless of VHL status. In accordance with these obsevations, we observed herein that Lim1 expression is not dependent on VHL status suggesting that Lim1 expression is not associated with the VHL/HIF system in human CCC; although some studies have reported crosstalk between SHH-Gli pathway, that is at least partly responsible for Lim1 expression in this disease, and HIF pathways in other systems (Bar et al., 2007) . To our best knowledge, Lim1 in renal cell carcinoma V Dormoy et al the Lhx1 gene has not been shown to be mutated in cancer. The cause of Lim1 reexpression in human CCC is probably multiple. For example, Lim1 is a downstream effector of SHH-Gli signaling functions (Dormoy et al., 2009 ) and its expression is regulated by Pax2, FGFs and Wnts factors, which have been shown to be involved in human CCC tumorigenesis (Strutz et al., 2002; Hueber et al., 2008; Kawakami et al., 2009) . As the list of developmental markers shown to be involved in human CCC growth is increasing progressively, it would be interesting to go further into this mechanism to help dissect the molecular puzzle accounting for kidney tumorigenesis. With the results presented herein, it will be important to identify all markers and/or pathways susceptible to lead to Lim1 expression and this is the purpose of the ongoing work in our laboratory.
The role of Lim1 has never been assessed in human CCC, and in fact, nor in any cancer type. Here, we show that Lim1 is constitutively expressed and activated in human CCC both in vitro in cultured cells and in vivo in freshly harvested tumors, and in tumors grown in nude mice. Our results showed that Lim1 is turned towards tumor cell growth in human CCC. The inhibition of Lim1 was equally active in decreasing growth whether cells are expressing VHL or not. In human CCC, we show in both cultured cells and tumor-bearing nude mice, that Lim1 stimulates essentially cell proliferation and in a lesser degree inhibits cell death; and Lim1 silencing did not induce senescence.
Very importantly, we observed that Lim1 silencing blocks tumor progression, an effect that was related to the decrease in Lim1 expression. An interesting observation is that Lim1 silencing in tumors of human CCC-bearing nude mice did not affect tumor vascularization. It should be noted, however, that reports dealing with the prognostic value of vascularisation in human CCC have shown either no effect on patient survival, better survival, or worse prognosis (MacLennan and Bostwick, 1995; Nativ et al., 1998; Imao et al., 2004; Yao et al., 2007) .
The spread of cancer cells from the primary tumor to a distant site involves many of the invasive processes normally required for wound healing, including migration through the local connective tissue, invasion of the vasculature and the connective tissue at a distant site, or angiogenesis. We have tested some of the markers responsible for the acquisition of metastatic properties including fibronectin (Meng et al., 2009) , the matrix metalloproteinase MMP9 (Ryschich et al., 2009) , the focal adhesion plaque-associated cytoskeleton protein paxillin (Tang et al., 2008) , tenascin-C (Chen et al., 2009) as well as tubulin and actin (Hall, 2009) . The expression of all of these markers was substantially, and time-dependently, decreased by Lim1 silencing both in vitro in cultured cells and in vivo in human CCCbearing nude mice. Although we do not have clear explanations for the time-dependency of Lim1 effects on target proteins expression and/or activation, this may be the consequence of either a direct transcriptional effect of Lim1 or an indirect effect through the various signaling pathways affected by Lim1. The observation that Lim1 also controls b-actin expression suggests that in addition to the potential interaction of Lim1 with b-actin through Lim domains, Lim1 may also control its expression in cancer cells; an hypothesis that would need to be verified by specific experiments. Our results strongly suggest that Lim1 is part of the molecular network involved in tumor spread and invasion in human CCC. In accordance with that hypothesis, tenascin-C expression was shown to be a significant predictor of metastasis in human CCC (Ohno et al., 2008) . It will be interesting in the near future to define more precisely the role of Lim1 in tumor invasion, and this should lead to a better comprehension of the molecular mechanism involved in metastatic spread of human CCC.
The PI3K/Akt, NF-kB, MAPK, Notch and SHH signaling pathways are activated constitutively in human CCC (Sourbier et al., 2006 Huang et al., 2008; Sjolund et al., 2008; Dormoy et al., 2009 ) strongly suggesting that tumor cells reactivate developmental pathways for their growth, invasion and immune escape. Here, we show that Lim1 regulates the activation of the oncogenic pathways PI3K/Akt, NF-kB and MAPK; and also regulates the expression and/or activity of a broad range of oncogenic pathways and molecular factors involved in cell apoptosis, proliferation and movements, and in angiogenesis processes. Thus, Lim1 clearly appears as a pivotal transcription factor able to regulate the expression and/or activation of various oncogenic and angiogenic pathways in human RCC. It will be important in future works to understand how the transcription factor Lim1 affects the expression/ activation of all these pathways and targets, and this is also the purpose of the ongoing studies in our laboratory.
Our results indicate that Lim1 acts as an oncogene concerning RCC, and its blockade may represent a new efficient and safe therapeutic option for this refractory disease either alone or in combination. The identification of Lim1 as a new prognostic factor may also emerge from these results.
Materials and methods
Cell culture and reagents
Human CCC cell lines either deficient in VHL (786-0, A498) or expressing VHL (ACHN, Caki-1, Caki-2) were obtained from the American Type Culture Collection (Manassas, VA, USA). The cells were maintained in DMEM (Invitrogen, CergyPontoise, France) supplemented with 10% fetal bovine serum and 1% antibiotics (penicillin/streptamycine, Gibco, Cergy Pontoise, France) in a 10% CO 2 atmosphere. Clones of 786-0 cells transfected either with human VHL gene (786-0-VHL), inactive truncated human VHL gene (786-0-DVHL), or the vector alone only pCR3-Uni (786-0-V) were also used and maintained in the same medium supplemented with gentamycine (500 mg/ml, Invitrogen).
Human tumor biopsies
The tumor and normal corresponding tissue of 44 patients were obtained in collaboration with the Department of Urology (Professor D Jacqmin and Professor H Lang) of the (Sagalowsky, 2002): 9 pT1a, 7 pT1b, 7pT2, 3 pT3a, 15 pT3b, 3 pT4. Immediately after surgical resection, tissues were fresh frozen and kept in liquid nitrogen until RNA and protein expression analysis.
Western blot analysis
Protein extractions and membrane preparations were performed as described (Massfelder et al., 2004) . Membranes were incubated overnight at 4 1C with the appropriate dilution of the following primary antibodies: anti-Akt (1:250; Millipore, Molsheim, France), anti-phospho-Akt (1:150; Ozyme, Cell Signaling local distributor, Saint-Quentin-en-Yvelines, France), anti-NF-B (1:2000; Millipore), anti-phospho-NF-kB (1:250; Ozyme), anti-glycogen synthase kinase-3a/b (1:1000; Millipore), anti-phospho-glycogen synthase kinase-3a/b (Ser21/9 ; 1:500; Millipore) anti-Erk1/2 (1:1000; Ozyme), anti-phospho-Erk1/2 (1:1000; Millipore), anti-glyceraldehyde-3-phosphate-dehydrogenase (1:500; Millipore), anti-a-tubulin (1:500; Abcam, Paris, France), anti-b-actin (1:500; Millipore), anti-paxillin (1:500; Invitrogen), anti-fibronectin (1:500; Ozyme), anti-tenascin-C (1:500; Ozyme), anti-MMP-9 (1:500; Millipore), and anti-Lim1 (1:500, Millipore). For visualization of protein gel loading, an anti-b-actin (1:5000; Sigma-aldrich, St Quentin Fallavier, France) or anti-glyceraldehyde-3-phosphate-dehydrogenase (1:500, Millipore) antibody was used. The appropriate horseradish peroxidase-conjugated secondary antibody was used. Immunoreactivity was visualized with the enhanced chemiluminescence immunoblotting detection kit (Millipore).
Proteome array analysis
The proteome Profiler Arrays were used according to the manufacturer's protocol (R&D systems, Lille, France). 786-0 cells were seeded in 6-well plates (100 000 cells/ml), grown for 24 h, and then transiently transfected for 24-48 h with siRNA targeting Lhx1 or vehicle (Ctl). The cells were lysed according to the manufacturer's protocol. The lysate was added to the membrane array, which was incubated overnight with the detection antibody cocktail. After washing, secondary antibody (streptavidin-horseradish peroxidase, 1:2000 dilution) was added. Protein signals were detected by the enhanced chemiluminescence system (Millipore). Western analysis was done on total cell lysates. Duplicate gene signals on the array were quantified using Bio1D software (Vilber Lourmat, Marne-laValle´e, France). Results are expressed as average pixel density.
Real-time quantitative reverse transcription-PCR analysis
Total RNAs were extracted from CCC cells using the Trizol method according to the manufacturer's protocol (Invitrogen). In all, 5 mg of total RNA were reverse transcribed in a reaction buffer (Invitrogen) and non-specific primer p(dT) 15 Cell density CCC cell proliferation was assessed by counting adherent cells, as described (Massfelder et al., 2004) . RCC cells were seeded in 24-well plates (20 000 cells/ml), grown for 24 h, and then transiently transfected for 24-96 h with various concentrations of siRNAs expressing vector targeting Lhx1, siCtl or vehicle (Ctl). Cell density was assessed either alone or in combination with cyclopamine (LC Laboratories, Woburn, MA, USA), SB216763 (glycogen synthase kinase-3 inhibitor, SigmaAldrich), LY294002 (PI3K inhibitor, Sigma-Aldrich), BAY 11-7085 (NF-B inhibitor, Calbiochem, Fontenay-sous-Bois, France), or U0126 (MAPK inhibitor, Calbiochem). We have previously shown the specificity of LY294002, BAY11-7085 and cyclopamine on their specific targets at the concentration used by western blot (Sourbier et al., 2006 Agouni et al., 2007; Dormoy et al., 2009) . The specificity at the concentration of the other inhibitors has been shown in numerous studies.
Bromodeoxyuridine incorporation CCC cells were seeded in 96-well plate (20 000 cells/ml) and grown for 24 h. Cells were transiently transfected for 24 h to 96 h with siLhx1, siCtl or vehicle (Ctl). Tests were then realized according to the protocol of the manufacturer (Calbiochem, Merck KGaA, Darmstadt, Germany).
Fluorescence-activated cell sorting analysis CCC cells were seeded in 6-well plates (20 000 cells/ml) and grown for 24 h. Then cells were transiently transfected for 24 h to 96 h with siLhx1, or the corresponding volume of vehicle (Ctl). Floating and adherent cells were harvested and resuspended in incubation buffer (100 ml/500,000 cells: 140 mmol/l NaCl, 5 mmol/l CaCl 2 and 10 mmol/l 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer) containing Annexin V-FITC and propidium iodide (5 mg/ml) and incubated in a dark chamber at 4 1C for 10 min. After centrifugation, the supernatant was withdrawn and cells were fixed in a dark chamber in 200 ml of formol 1% at 4 1C for 10 min. After centrifugation, cells were resuspended in 200 ml incubation buffer and subjected to fluorescence-activated cell sorter. Fluorescence analysis was performed using fluorescence-activated cell sorter flow cytometer (BD, Le Pont de Claix, France), and the fraction of viable cells and apoptosis cells was determined using FCS express software (DeNovo Software, Los Angeles, CA, USA).
Scratch (wound) assay
786-0 and Caki-1 cells were grown in 24-well plates to confluence and formed a monolayer covering the surface of the entire plate. Cells were transiently transfected with siLhx1
Lim1 in renal cell carcinoma V Dormoy et al or siCtl. After 24 h of treatment, the wound was created in the center of the cell monolayer by the gentle removal of the attached cells with a sterile plastic scratcher. Debris was removed by PBS wash, and the cells received fresh media with the same conditions as before. The ability of the cells to migrate into the wound area was assessed after 24 h by comparing the 0-, 12-and 24-h micrographs of several marked points along the wounded area at each plate. The percentage of recovered wound area was calculated by dividing the recovered area after 12 h or 24 h by the initial wound area at zero time.
Migration and invasion assays
The invasiveness of renal cancer cells was assessed based on the invasion of cells through Matrigel-coated transwell inserts. In brief, the upper surface of a filter (pore size, 8.0 mm; Millipore) was coated with basement membrane Matrigel (ECL Matrix, Millipore). Cells transiently transfected with siLhx1 or not were suspended in serum-free DMEM containing the desired dose of reagents. Then 100 000 cells were added to the upper chamber and incubated for 24 h-96 h. After incubation and trypsinization of the filter, cells that had migrated from the upper to the lower side (which contains DMEM with 10% fetal bovine serum) of the filter were counted. Tumor cell invasiveness was defined as the total number of invaded cells. Each experiment was carried out in triplicate wells. The migration ability of renal cancer cells was assessed in the same way as described above, but nonMatrigel-coated transwell inserts were used.
Xenograft tumor model
All animal studies were in compliance with the French animal use regulations. A total of 10 million 786-0 cells were injected subcutaneously into the skin of 4-week-old athymic male mice (SWISS nu-/nu-; Charles River Laboratories, l 0 Arbresle, France). Tumor volumes were measured as previously described (Massfelder et al., 2004) .We begun drug injections in the two groups when 786-0 tumors had grown to an overall volume of 100 mm 3 . The protocol was injection of siLhx1 ('siRNA in vivo ready' Lhx1 s8165 (exon 2) or s8166 (exon1) targeting the Lhx1 RNA) intra tumoral (iTu) at 1 nmol per mouse three times a week, the control groups receiving the siCtl negative or the vehicle alone (PBS) at the same time period. The treatment was followed for 4 weeks and tumors growth was measured three times a week. At the end of the treatment, animals were killed and the tumors were harvested, paraffin embedded, and cut in 4-mm-thick sections for subsequent immunohistochemical analysis as described before, for the proliferative index, the apoptotic index and the neovascularisation , and snap-frozen for PCR or western blot analysis.
Statistical analysis
All values are expressed as mean±s.e.m. Values were compared using multifactorial analysis of variance followed by the Student-Newman-Keul's test for multiple comparisons. A Po0.05 was considered significant.
